(Q44659967)

5 December 2017

title

Ondansetron and metformin-induced gastrointestinal side effects (English)

1 reference

5 December 2017

Ondansetron and Metformin-Induced Gastrointestinal Side Effects (English)

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

3 April 2024

1 reference

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

3 April 2024

author name string

Magaly Roa

2

1 reference

5 December 2017

Fatima Torrico

3

1 reference

5 December 2017

Irene S. Hoffmann

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624284

3 April 2024

Luigi X. Cubeddu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624284

3 April 2024

language of work or name

1 reference

1 November 2003

1 reference

full work available at URL

5 December 2017

http://journals.lww.com/00045391-200311000-00012

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

American Journal of Therapeutics

3 April 2024

published in

1 reference

5 December 2017

volume

10

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

447-451

1 reference

5 December 2017

1

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

3 April 2024

Metformin

2

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

3 April 2024

3

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Diarrhea and Metformin in a Diabetic Clinic

3 April 2024

4

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Comparative tolerability profiles of oral antidiabetic agents

3 April 2024

5

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

3 April 2024

Metformin

7

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

New oral agents for type II diabetes.

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Relative activities of substances related to 5-hydroxytryptamine as depolarizing agents of superior cervical ganglion cells

3 April 2024

9

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

1-(m-chlorophenyl)-biguanide, a potent high affinity 5-HT3 receptor agonist.

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

The agonist properties of m-chlorophenylbiguanide and 2-methyl-5-hydroxytryptamine on 5-HT3 receptors in N1E-115 neuroblastoma cells

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret

3 April 2024

13

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting

3 April 2024

14

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Cisplatin increases the release of 5-hydroxytryptamine (5-HT) from the isolated vascularly perfused small intestine of the guinea-pig: Involvement of 5-HT3 receptors

3 April 2024

15

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies

3 April 2024

17

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine

3 April 2024

19

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Autoreceptors can modulate 5-hydroxytryptamine release from porcine and human small intestine in vitro

3 April 2024

20

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

3 April 2024

21

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Antiemetic activity of ondansetron in acute gastroenteritis

3 April 2024

23

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery

3 April 2024

24

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy

3 April 2024

26

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors

3 April 2024

27

1 reference

https://api.crossref.org/works/10.1097/00045391-200311000-00012

3 April 2024

Identifiers

1 reference

5 December 2017

1 reference